HUP0400495A2 - Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény - Google Patents

Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény

Info

Publication number
HUP0400495A2
HUP0400495A2 HU0400495A HUP0400495A HUP0400495A2 HU P0400495 A2 HUP0400495 A2 HU P0400495A2 HU 0400495 A HU0400495 A HU 0400495A HU P0400495 A HUP0400495 A HU P0400495A HU P0400495 A2 HUP0400495 A2 HU P0400495A2
Authority
HU
Hungary
Prior art keywords
oral mucosal
apomorphine
dosage forms
administration via
tissue
Prior art date
Application number
HU0400495A
Other languages
English (en)
Inventor
John D. Bollinger
Craig W. Davis
Pramod K. Gupta
Robert K. Mansfield
Raymundo A. Sison
Paul E. Stach
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of HUP0400495A2 publication Critical patent/HUP0400495A2/hu
Publication of HUP0400495A3 publication Critical patent/HUP0400495A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely apomorfin vagygyógyszerészetileg elfogadható sója vagy prodrugja terápiásan hatásosmennyiségét tartalmazza egy 10-95 tömeg%-ban dextránt tartalmazóhordozóval kombinációban. A találmány oltalmi körébe tartozik egy azapomorfin szájnyálkahártyán keresztül történő adagolására szolgálótabletta dózis forma is, amely 2-10 mg apomorfint tartalmaz 10-95 mgdextránt tartalmazó hordozóanyaggal kombinációban. Ó
HU0400495A 1999-12-30 2000-12-19 Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue HUP0400495A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47584499A 1999-12-30 1999-12-30
PCT/US2000/034548 WO2001049292A1 (en) 1999-12-30 2000-12-19 Oral mucosal dosage forms of apomorphine

Publications (2)

Publication Number Publication Date
HUP0400495A2 true HUP0400495A2 (hu) 2004-06-28
HUP0400495A3 HUP0400495A3 (en) 2007-05-02

Family

ID=23889387

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400495A HUP0400495A3 (en) 1999-12-30 2000-12-19 Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue

Country Status (14)

Country Link
EP (1) EP1242088A1 (hu)
JP (1) JP2004501065A (hu)
CN (1) CN1414853A (hu)
AU (1) AU2440901A (hu)
BR (1) BR0012822A (hu)
CA (1) CA2394297A1 (hu)
CZ (1) CZ20022245A3 (hu)
HK (1) HK1051315A1 (hu)
HU (1) HUP0400495A3 (hu)
IL (1) IL150034A0 (hu)
MX (1) MXPA02006034A (hu)
NO (1) NO20023190L (hu)
PL (1) PL366204A1 (hu)
WO (1) WO2001049292A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
SI1617823T1 (sl) * 2003-01-24 2019-07-31 Nicachet Ab Vrečka, ki obsega nikotinski sestavek za transmukozno dajanje
SE0302947D0 (sv) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
CA2562391A1 (en) * 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
AU2010259971C1 (en) * 2009-06-12 2017-02-16 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
WO2020243538A1 (en) * 2019-05-31 2020-12-03 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0865789T3 (da) * 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2001049292A1 (en) 2001-07-12
PL366204A1 (en) 2005-01-24
EP1242088A1 (en) 2002-09-25
BR0012822A (pt) 2004-03-09
CA2394297A1 (en) 2001-07-12
NO20023190L (no) 2002-08-29
AU2440901A (en) 2001-07-16
JP2004501065A (ja) 2004-01-15
CZ20022245A3 (cs) 2002-10-16
HK1051315A1 (zh) 2003-08-01
CN1414853A (zh) 2003-04-30
IL150034A0 (en) 2002-12-01
MXPA02006034A (es) 2004-08-23
NO20023190D0 (no) 2002-07-01
HUP0400495A3 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
HUP0302571A2 (hu) Szerves vegyületek keverékét tartalmazó gyógyszerkészítmény légúti betegségek kezelésére
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2255287T3 (es) Composiciones para el tratamiento de la leucemia linfocitica cronica.
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
HUP0203162A2 (hu) NSAID és EGFR-kináz gátlót tartalmazó készítmény vastagbélpolipok és vastagbélrák kezelésére vagy visszaszorítására
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
HK1083452A1 (en) Pharmaceutical compositions
BG105173A (en) Novel salt form of pantoprazole
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AP2003002763A0 (en) Controlled release formulations for oral administration
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
HUP0204511A2 (en) Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
HUP0400127A2 (hu) Paracetamolt tartalmazó lenyelhető tabletta
JP2002540148A5 (hu)
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
HUP0201629A2 (hu) Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees